Immunization with an Escherichia coli-Produced Hepatitis E Virus Genotype 3 Virus-like Particle (HEV-3_p495) Confers Protection Against HEV-3 and HEV-4 Challenge in Pigs.
- 1Center for Experimental Medicine, Jichi Medical University School of Medicine, 3311-1 Yakushiji, Shimotsuke 329-0498, Tochigi, Japan.
- 2Division of Virology, Department of Infection and Immunity, Jichi Medical University School of Medicine, 3311-1 Yakushiji, Shimotsuke 329-0498, Tochigi, Japan.
Abstract
Hepatitis E virus (HEV) genotypes 3 and 4 are major zoonotic pathogens, with domestic pigs serving as an important reservoir. Vaccination of pigs may therefore help reduce HEV circulation and zoonotic transmission. We evaluated the protective efficacy of an Escherichia coli-produced HEV-3 virus-like particle (VLP), HEV-3_p495, against homologous HEV-3 and heterologous HEV-4 challenge in pigs. Juvenile pigs vaccinated three times with either 80 or 400 μg of HEV-3_p495 remained negative for HEV RNA in serum and feces during prolonged cohabitation with naturally HEV-3-infected pigs, whereas all non-vaccinated controls became infected. At market age, vaccination also provided strong protection against intravenous HEV-3 challenge, with complete protection against detectable infection in the four-dose group and in two of three pigs in the three-dose group. Importantly, HEV-3_p495 conferred cross-protection against HEV-4 following cohabitation exposure. Two-dose vaccination prevented detectable infection in two of three young pigs and delayed fecal virus detection without viremia in the remaining pig. At market age, all vaccinated pigs remained negative for HEV RNA in serum and feces following HEV-4 exposure, whereas all non-vaccinated controls became infected. These findings provide proof-of-concept evidence for homologous and cross-genotype protection by HEV-3_p495 and support its further evaluation as a candidate swine vaccine for reducing HEV infection and shedding.
Related
- mRNA vaccines expressing Plasmodium falciparum CSP with distinct antigen localisation profiles induce differential humoral immunity and partial protection in a mouse sporozoite challenge model
- Avidity as a marker of protection against hepatitis E during a genotype 1 outbreak in South Sudan
- Contact without protection: high antenatal attendance, minimal hepatitis B testing in Nigerias mother-to-child prevention cascade -- how far from elimination?
- Correlates of Protection and Response Durability of the RTS,S Vaccine in Four Malaria Challenge Studies
- Journey to immunization service: identifying barriers and enablers to routine immunization service uptake among communities residing in urban slum areas of Addis Ababa, Ethiopia, 2023
BibTeX
@article{kunita2026immunization,
title = {{Immunization with an Escherichia coli-Produced Hepatitis E Virus Genotype 3 Virus-like Particle (HEV-3_p495) Confers Protection Against HEV-3 and HEV-4 Challenge in Pigs.}},
author = {Satoshi Kunita and Masaharu Takahashi and Tominari Kobayashi and Kazumoto Murata and Hiroaki Okamoto},
journal = {Viruses},
year = {2026},
month = oct,
doi = {10.3390/v18101122},
url = {https://europepmc.org/article/MED/42944042},
note = {CC BY},
}
RIS
TY - JOUR
TI - Immunization with an Escherichia coli-Produced Hepatitis E Virus Genotype 3 Virus-like Particle (HEV-3_p495) Confers Protection Against HEV-3 and HEV-4 Challenge in Pigs.
AU - Satoshi Kunita
AU - Masaharu Takahashi
AU - Tominari Kobayashi
AU - Kazumoto Murata
AU - Hiroaki Okamoto
PY - 2026
DA - 2026/10/10
JO - Viruses
DO - 10.3390/v18101122
UR - https://europepmc.org/article/MED/42944042
AB - Hepatitis E virus (HEV) genotypes 3 and 4 are major zoonotic pathogens, with domestic pigs serving as an important reservoir. Vaccination of pigs may therefore help reduce HEV circulation and zoonotic transmission. We evaluated the protective efficacy of an Escherichia coli-produced HEV-3 virus-like particle (VLP), HEV-3_p495, against homologous HEV-3 and heterologous HEV-4 challenge in pigs. Juvenile pigs vaccinated three times with either 80 or 400 μg of HEV-3_p495 remained negative for HEV RNA in serum and feces during prolonged cohabitation with naturally HEV-3-infected pigs, whereas all non-vaccinated controls became infected. At market age, vaccination also provided strong protection against intravenous HEV-3 challenge, with complete protection against detectable infection in the four-dose group and in two of three pigs in the three-dose group. Importantly, HEV-3_p495 conferred cross-protection against HEV-4 following cohabitation exposure. Two-dose vaccination prevented detectable infection in two of three young pigs and delayed fecal virus detection without viremia in the remaining pig. At market age, all vaccinated pigs remained negative for HEV RNA in serum and feces following HEV-4 exposure, whereas all non-vaccinated controls became infected. These findings provide proof-of-concept evidence for homologous and cross-genotype protection by HEV-3_p495 and support its further evaluation as a candidate swine vaccine for reducing HEV infection and shedding.
SN - 1999-4915
ER -